Latest Intellectual Property News

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Nufarm Limited reported a 3% revenue increase to $1.81 billion for the half-year ended March 2025, driven by Crop Protection volume growth. However, net profit after tax fell 39% amid fish oil pricing pressures and higher operating costs, prompting the board to withhold an interim dividend.

Nufarm Limited posted a 3% revenue increase to $1.81 billion for the half-year ending March 2025, driven by Crop Protection growth, yet profits fell sharply due to omega-3 inventory write-downs and higher costs. The company withheld its interim dividend amid ongoing operational challenges.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

A shareholder has lodged a formal application with the Takeovers Panel challenging FBR Limited’s recent share placements and governance practices, raising concerns over disclosure and shareholder engagement.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Archer Materials has teamed up with UK-based Paragraf to fast-track development of its Biochip sensor for at-home chronic kidney disease testing, aiming to enhance accuracy and product readiness over six months.

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

Metals X Limited has committed $5 million to acquire a significant stake in Elementos Limited through a private placement, positioning itself as a key player in the tin development sector.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.